Catheter Precision, Inc. (NYSEAMERICAN:VTAK) Short Interest Update

Posted by Stanley Muller on Jul 29th, 2026

Catheter Precision, Inc. (NYSEAMERICAN:VTAK – Get Free Report) was the recipient of a large increase in short interest during the month of July. As of July 15th, there was short interest totaling 574,897 shares, an increase of 98.3% from the June 30th total of 289,957 shares. Currently, 16.9% of the company’s shares are sold short. Based on an average daily trading volume, of 30,260,865 shares, the days-to-cover ratio is presently 0.0 days.

Catheter Precision Trading Up 1.0%

Shares of VTAK traded up $0.00 during mid-day trading on Wednesday, hitting $0.28. 1,236,975 shares of the company’s stock traded hands, compared to its average volume of 4,397,643. The company has a quick ratio of 0.06, a current ratio of 0.06 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $1.02 million, a P/E ratio of -0.02 and a beta of -1.07. The business’s 50-day moving average price is $0.83 and its 200-day moving average price is $1.21. Catheter Precision has a 1 year low of $0.23 and a 1 year high of $4.31.

Catheter Precision (NYSEAMERICAN:VTAK – Get Free Report) last announced its quarterly earnings results on Monday, May 18th. The company reported ($1.39) EPS for the quarter, topping analysts’ consensus estimates of ($20.90) by $19.51. The company had revenue of $0.43 million during the quarter, compared to analyst estimates of $1.60 million. Catheter Precision had a negative return on equity of 76.51% and a negative net margin of 1,297.56%.

Institutional Investors Weigh In On Catheter Precision

An institutional investor recently bought a new position in Catheter Precision stock. Millennium Management LLC bought a new stake in shares of Catheter Precision, Inc. (NYSEAMERICAN:VTAK – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund bought 34,721 shares of the company’s stock, valued at approximately $64,000. Millennium Management LLC owned approximately 2.08% of Catheter Precision at the end of the most recent quarter. Hedge funds and other institutional investors own 20.34% of the company’s stock.

About Catheter Precision

(Get Free Report)

Catheter Precision, Inc (NYSE American: VTAK) is a medical device company specializing in the design, development and manufacture of catheter-based products for interventional cardiology and peripheral vascular procedures. The company’s core business centers on balloon catheter platforms, offering both standard and specialty catheter configurations that address applications ranging from percutaneous transluminal angioplasty (PTA) to percutaneous transluminal coronary angioplasty (PTCA). Catheter Precision’s product portfolio is engineered to meet diverse clinical needs, including high-pressure dilation, scored and cutting balloon therapies, and drug-coated balloon delivery.

All of Catheter Precision’s products are developed in its ISO 13485-certified, FDA-registered manufacturing facility in Bloomington, Minnesota.